Get the Stockscreener App
255.25
0.79%
2.00
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $255.25, with a volume of 220.57K.
It is up +0.79% in the last 24 hours and up +19.72% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$253.25
Open:
$255.11
24h Volume:
220.57K
Relative Volume:
0.98
Market Cap:
$5.12B
Revenue:
$274.48M
Net Income/Loss:
$153.56M
P/E Ratio:
34.61
EPS:
7.3755
Net Cash Flow:
$114.06M
1W Performance:
+4.92%
1M Performance:
+19.72%
6M Performance:
+32.51%
1Y Performance:
+121.94%
1-Day Range:
$250.37
$258.21
1-Week Range:
$245.00
$259.03
52-Week Range:
$110.00
$259.03
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
255.25 | 5.08B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals director Jason Haas sells $1.65m stock By Investing.com - Investing.com South Africa
Ligand (LGND) director exercises options, sells 6,461 common shares around $255–$256 - Stock Titan
Kozarich Sells Shares of Ligand Pharmaceuticals - Intellectia AI
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? - Yahoo Finance
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Ligand Pharmaceuticals Stock 9-Day Winning Spree: Stock Climbs 11% - Trefis
Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak - Trefis
Insider Sell: John Lamattina Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharma director John L. LaMattina sells $1.15 million stock - Investing.com
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock By Investing.com - Investing.com India
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock - Investing.com UK
Ligand Pharmaceuticals Director Sold Shares Worth Over $1.1M - TradingView
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
Director sells 4,591 Ligand (LGND) shares in multiple open-market trades - Stock Titan
LGND (NASDAQ) Form 144 shows 4,000-share option exercise and restricted stock notices - Stock Titan
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date - Benzinga
JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo - Stock Titan
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by GW&K Investment Management LLC - MarketBeat
Franklin Resources Inc. Acquires 266,304 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $254.46 By Investing.com - Investing.com Nigeria
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand Pharmaceuticals stock hits 52-week high at $254.46 - Investing.com
Ligand Pharmaceuticals to hold Investor Day in NYC on Dec 8, 2026, sharing strategy and financial outlook. - Pluang
Ligand Announces 2026 Investor Day in New York City - The Manila Times
Los Angeles Capital Management LLC Boosts Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
BNP Paribas Financial Markets Buys 30,865 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition - Stock Titan
Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants - Stock Titan
Director John L. Lamattina receives LGND (LGND) RSUs and stock options - Stock Titan
Ligand (LGND) director John Kozarich receives RSUs and stock options grant - Stock Titan
Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants - Stock Titan
Ligand (LGND) director Nancy Ryan Gray receives new RSUs and options - Stock Titan
Ligand Pharma Shareholders Back Governance and Incentive Plan - TipRanks
Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan - Stock Titan
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million - AOL.com
Cibc World Market Inc. Has $4.85 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Bank of America Securities Remains a Buy on Ligand Pharma (LGND) - The Globe and Mail
Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing - Moomoo
Ligand Pharmaceuticals CLO Reardon sells $1.1 million in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.1 million in stock - Investing.com
Ligand (NASDAQ: LGND) CLO sells 5,000 shares, exercises options - Stock Titan
Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote - Bez Kabli
Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) - TMX Newsfile
Legend Bio rises after early-stage data for in vivo CAR-T therapy - Seeking Alpha
How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets - Yahoo Finance
Free float of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Number of shareholders of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Future Fund LLC Purchases Shares of 9,280 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Insider Unloading: Octavio Espinoza Sells Options, Realizes $307K - Benzinga
Ligand Pharma (LGND) Receives a Buy from Bank of America Securities - The Globe and Mail
Ligand (NASDAQ: LGND) CFO exercises 1,736 stock options, now holds 27,679 shares - Stock Titan
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ligand Pharmaceuticals Inc Stock (LGND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haas Jason | Director |
Jun 12 '26 |
Sale |
255.58 |
6,461 |
1,651,320 |
4,981 |
| Aryeh Jason | Director |
Jun 11 '26 |
Sale |
250.00 |
4,500 |
1,125,000 |
102,580 |
| Aryeh Jason | Director |
Jun 10 '26 |
Sale |
250.00 |
500 |
125,000 |
107,080 |
| LAMATTINA JOHN L | Director |
Jun 10 '26 |
Sale |
250.88 |
4,591 |
1,151,774 |
26,969 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):